Biotechnology company Aardvark Therapeutics submitted an IPO application for the US stock market, aiming to raise USD 100 million
I'm PortAI, I can summarize articles.
Biotechnology company Aardvark Therapeutics has submitted an IPO application to the U.S. Securities and Exchange Commission, planning to raise $100 million. The company focuses on developing novel small molecule therapies for metabolic diseases, with its main candidate drug ARD-101 currently undergoing Phase III clinical trials, with data expected to be released in early 2026. Aardvark was founded in 2017 and plans to list on NASDAQ under the ticker symbol AARD. Morgan Stanley and others are the joint bookrunners for this transaction
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments